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Abstract
Background: As schizophrenia patients are typically suspicious of, or are hostile to changes they may be
reluctant to accept generic substitution, possibly affecting compliance. This may counteract drug costs savings due
to less symptom control and increased hospitalization risk. Although compliance losses following generic
substitution have not been quantified so far, one can estimate the possible health-economic consequences. The
current study aims to do so by considering the case of risperidone in Germany.
Methods:  An existing DES model was adapted to compare staying on branded risperidone with generic
substitution. Differences include the probability of non-compliance and medication costs. Incremental probability
of non-compliance after generic substitution was varied between 2.5% and 10%, while generic medication costs
were assumed to be 40% lower. Effect of medication price was assessed as well as the effect of applying
compliance losses to all treatment settings. The probability of staying on branded risperidone being cost-effective
was calculated for various outcomes of a hypothetical study that would investigate non-compliance following
generic substitution of risperidone.
Results: If the incremental probability of non-compliance after generic substitution is 2.5%, 5.0%, 7.5% and 10%
respectively, incremental effects of staying on branded risperidone are 0.004, 0.007, 0.011 and 0.015 Quality
Adjusted Life Years (QALYs). Incremental costs are €757, €343, -€123 and -€554 respectively. Benefits of staying
on branded risperidone include improved symptom control and fewer hospitalizations. If generic substitution
results in a 5.2% higher probability of non-compliance, the model predicts staying on branded risperidone to be
cost-effective (NICE threshold of 30,000 per QALY gained). Compliance losses of more than 6.9% makes branded
risperidone the dominant alternative. Results are sensitive to the locations at which compliance loss is applied and
the price of generic risperidone. The probability that staying on branded risperidone is cost-effective would
increase with larger compliance differences and more patients included in the hypothetical study.
Conclusion: The model predicts that it is cost-effective to keep a patient with schizophrenia in Germany on
branded risperidone instead of switching him/her to generic risperidone (assuming a 40% reduction in medication
costs), if the incremental probability of becoming non-compliant after generic substitution exceeds 5.2%.
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Background
Compliance amongst patients with schizophrenia is an
important issue. Reported non-compliance rates for
patients suffering from schizophrenia are relatively high,
ranging from 40% to 50% [1-5] Non-compliance has
been found to significantly increase the likelihood of hos-
pitalization, inpatient charges, switching or augmenting
therapy and symptoms.[1,6,7] Factors influencing com-
pliance behaviour of patients with schizophrenia can be
classified into patient-related (e.g. nature of the illness
and attitude towards the illness), environment-related
(e.g. social support and therapeutic environment), physi-
cian-related (e.g. clinician-patient relation and informa-
tion) and treatment-related (e.g. side effects and route of
administration).[8]
With regard to treatment related factors, poor compliance
can result from generic substitution; patients might be
reluctant to accept a switch to a generic version due to dif-
ferences in colorants, size, shape or even name.[9,10]
Ganther et al. showed that generic alternatives are also
thought to be less safe and less effective than their
branded equivalents by at least 20% to 30% of consum-
ers.[11] To some extent this applies to all medications,
however the specific nature of schizophrenia aggravates
poor compliance. Patients suffering from schizophrenia
are suspicious to change in general and often develop par-
anoia and suffer from delusions. Some authors have even
noted that when patients are stable on a certain medica-
tion for schizophrenia they may not readily accept a sud-
den switch to a generic version and may even regard it as
a poisoning attempt.[12] In such situations it may be cost-
saving/cost-effective in the long-term to maintain a stable
regimen. Generic substitution immediately saves drug
costs but, when compliance is negatively affected, this can
be outweighed by poorer symptom control and increased
hospitalization costs. According to an international
review of the costs of schizophrenia, a modest 1 to 9% of
all direct health care costs in schizophrenia are attributed
to drug costs, whereas one to two-thirds are attributed to
hospitalization.[13]
This report quantifies the health-economic impact of
generic substitution involving a possible compliance loss,
by considering the case of oral risperidone in Germany
(for which the patent expired in December 2007) using a
pharmaco-economic Discrete Event Simulation (DES)
model.
Methods
An existing DES model, previously used to asses the cost-
effectiveness of long-acting injectable risperidone in Ger-
many[14], was adapted to conduct the pharmaco-eco-
nomic analysis of generic substitution of oral risperidone
in Germany. The advantages of a DES model is that
patient histories and patient heterogeneity can easily be
taken into account when modelling future events, as
opposed to cohort models (e.g. decision tree or markov
model).[15,16] As schizophrenia is a complex, highly het-
erogeneous disease, DES is best suited to perform cost-
effectiveness analyses for this indication.[17] Details of
the model can be found elsewhere[15,18] however a brief
description of the model will be provided with special
attention given to the issue of compliance.
The model simulates individual patients suffering from
schizophrenia over a period of five years and during this
time a patient can be in two different health states: in a
state of relapse or between relapses. Throughout the entire
model horizon, the severity of a patient's symptoms is
monitored by their Positive and Negative Syndrome Scale
(PANSS). The PANSS score is the main element that influ-
ences the core model outcomes: Quality Adjusted Life
Years (QALYs) and costs. There is a direct link between the
PANSS score and quality of life, indeed Lenert et al. found
the two variables to be negatively correlated[19] and qual-
ity of life is affected by the experience of side effects. An
indirect link between the PANSS score and costs is estab-
lished through the treatment setting chosen for a patient.
Patients with a higher PANSS score have a higher level of
dependency, leading to a higher probability of being
treated in a more intensive and thus more costly treatment
setting (e.g. day care departments or hospitals). In addi-
tion to treatment setting costs, total costs also consist of
medication costs and psychiatrist visit costs.
Compliance with medication is modelled as a dichoto-
mous variable; patients are compliant or non-compliant.
The probability of being compliant depends on the treat-
ment setting and a patient's health state. Firstly, it is mod-
elled so that patients in a more intensive treatment setting
(e.g. hospital) have a higher probability of being fully
compliant[20,21] Secondly, based on expert opinion, it is
modelled so that patients experiencing a relapse have a
lower probability of being fully compliant than patients
between relapses.
Compliance directly affects the PANSS score and the time
between relapses. This implies that quality of life and
costs are indirectly influenced by compliance. It is mod-
elled so that among patients who are compliant, medica-
tion leads to a 20% PANSS score reduction during
relapses, and a 5% reduction between relapses. [22-25]
Patients who are non-compliant gain no benefits from
medication; therefore they have no PANSS score reduc-
tion. If patients are compliant they are faced with a time
between relapses ranging from 1.1 years (most severe
patients) to 1.6 years (least severe patients). Patients who
are non-compliant face a shorter time between relapses of
between 0.29 to 0.43 years. [26-28]BMC Health Services Research 2009, 9:32 http://www.biomedcentral.com/1472-6963/9/32
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To assess the impact of generic substitution on the costs
and effects, the model was run with patients currently on
branded risperidone that either switch to generic risperi-
done or stay on branded risperidone. Therefore the treat-
ment arms are identical in every aspect except a difference
in compliance and a difference in medication costs. It is
modelled so that an individual patient who switches to
generic risperidone will have a higher probability of
becoming non-compliant than patients staying on
branded risperidone. There is no published literature that
quantifies the effect of generic substitution on compliance
in schizophrenia, therefore several incremental probabili-
ties of becoming non-compliant after generic substitution
within a reasonable range (0%–10% with steps of 2.5%)
have been explored. These differences are only applied to
the three least intensive treatment settings, as it was
expected that compliance differences would only hold in
treatment settings with low supervision. These treatment
settings are home-pp (patients visiting a private practice
psychiatrist), home-ia (patients visiting Institutsambulanz,
i.e outpatient clinics) and sheltered living. The other,
more intensive treatment settings are day care, hospital
and long term care institution. In a separate analysis, the
incremental probability of becoming non-compliant after
generic substitution is also applied to the latter treatment
settings. Medication costs for the generic risperidone arm
are assumed to be 40% lower compared to the branded
price, which is currently  7.41.[29]
Sensitivity Analysis
In a separate sensitivity analysis, the influence of different
generic prices for risperidone is tested. A price reduction
range of 20%–60% compared to the branded price is
applied and incremental effects and costs are recorded.
Also, an analysis of the Expected Impact of Sample Infor-
mation (EISI) on the probability of cost-effectiveness is
conducted. The reason for this is that currently there is no
study quantifying the compliance loss after generic substi-
tution with risperidone in patients with schizophrenia,
which makes the current analysis hypothetical to a certain
extent. Therefore, a logical next step may be to conduct a
study that quantifies the incremental probability of
becoming non-compliant after generic substitution. The
observed probability and corresponding uncertainty
could be used to estimate the probability of branded risp-
eridone being cost-effective.
Before conducting such a trial, the model can be used to
assess the impact of changing the trial size (at different
levels of expected compliance losses) on the probability to
be cost-effective. Thus, this analysis can be used to esti-
mate the number of patients required to show a certain
probability of cost-effectiveness at various levels of com-
pliance loss. This is performed in the model by choosing
different values of reasonable compliance losses, in this
case 6%, 6.5%, 7%, 7.5%, 8%, 9%, and 10%. Subse-
quently the probability of being cost-effective is calculated
assuming the above compliance differences are observed
in trials with 10, 20, 50, 100, 200 and 500 patients.
Clearly, the uncertainty surrounding the compliance loss
depends on the trial size; the more patients included in
the trial, the lower the uncertainty. The corresponding
probabilities of being cost-effective are estimated by per-
forming 42 (7 compliance losses * 6 trial sizes) multivar-
iate sensitivity analyses. It is expected that the lower the
uncertainty surrounding the incremental probability of
becoming non-compliant after generic substitution, the
higher the probability that staying on branded risperi-
done will be cost-effective (if the base case is cost-effec-
tive).
Results
Health and economic-related outcomes are presented in
Table 1. Clearly, the only difference in the outcomes for
branded risperidone and generic risperidone without
compliance loss are the drug costs. This difference is
explained by the 40% lower price of generic risperidone.
There are no other modelled differences between these
arms in terms of compliance, PANSS score reduction, side
effects or other parameters that may influence QALYs or
costs.
As could be expected, the larger the incremental probabil-
ity of becoming non-compliant after generic substitution,
the larger the average PANSS score is and the longer the
total relapse time and the more treatment setting costs
(particularly for day care and hospital) are incurred. Also,
the average time on risperidone decreases as patients will
switch treatment earlier due to lower efficacy. The QALYs
also decrease as compliance losses increase, resulting from
worsening symptom control (increase in PANSS scores).
Thus, incremental effects of branded risperidone versus
generic risperidone increase while incremental costs
decrease as compliance losses are higher. Worsening
symptom reduction implies lower quality of life and a
higher probability of going to a more intensive and thus
more costly treatment setting.
With a 2.5%, 5%, 7.5% and 10% incremental probability
of becoming non-compliant after switching to generic ris-
peridone, incremental effects of branded risperidone
compared to generic risperidone are 0.004, 0.007, 0.011
and 0.015 QALYs respectively. Incremental costs are
1,230,  757,  343, - 123 and - 544 respectively. Incre-
mental effects and costs both have a linear relationship
with the difference in compliance, as presented in Figure
1. With each percentage-point in compliance loss, incre-
mental costs decrease by  177. Incremental effects on theBMC Health Services Research 2009, 9:32 http://www.biomedcentral.com/1472-6963/9/32
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other hand increase with 0.0014 QALYs for each addi-
tional percentage-point in compliance loss.
Based on the linear lines representing the incremental
effects and costs, the incremental cost utility ratios (ICUR)
at various compliance differences can be determined by
dividing the incremental costs by the corresponding incre-
mental effects (see Figure 2). From Figure 2 it is clear that
if the compliance loss after generic substitution is more
than 5.2%, it may not be cost-effective (at a willingness to
pay (WTP) of  40,000 per QALY gained) to switch a
patient on branded risperidone to generic risperidone.
Also, at a compliance loss of more than 6.9%, it is esti-
mated that it may be cost-saving and lead to an increase in
health benefits to not switch a patient on branded risperi-
done to generic risperidone.
If the compliance loss with generic risperidone is applied
to all treatment settings (i.e. including the more intensive
treatment settings), the more favourable the option to
keep treating patients with branded risperidone. In this
analysis, a patient who is treated in a more intensive treat-
ment setting also has a higher probability of becoming
non-compliant after generic substitution. The minimal
incremental probability of becoming non-compliant after
generic substitution needs to be 4.5% in order for
branded risperidone to be cost-effective compared to
switching a patient to generic risperidone at a WTP thresh-
old of  40,000 per QALY gained. If the incremental prob-
ability of becoming non-compliant is more than 6.2%,
branded risperidone is estimated to generate cost-savings
and health-benefits compared to switching a patient to
generic risperidone (Figure 2).
Sensitivity Analysis
Table 2 shows the minimal compliance losses at which
staying on branded risperidone is cost-effective and is the
dominant treatment option respectively compared to
generic substitution at various prices for generic risperi-
done. Note that for this analysis, the incremental proba-
bility of becoming non-compliant after generic
substitution is only applied to the three least intensive
treatment settings. As can be expected, the lower the price
of generic risperidone, the higher the incremental proba-
bility of non-compliance must be in order for branded ris-
peridone to be cost-effective or dominant. A larger
Table 1: Model outcomes for several compliance losses with generic substitution
Branded Risp. Generic Risp. 0% Generic Risp. 2.5% Generic Risp. 5% Generic Risp. 7.5% Generic Risp. 10%
# Relapses 3.98 3.98 3.99 4.01 4.02 4.04
Total relapse time (yrs) 2.05 2.05 2.06 2.07 2.07 2.08
Average PANSS score 62.9 62.9 63.0 63.2 63.4 63.5
Time on risperidone 
(yrs)
1.16 1.16 1.14 1.13 1.12 1.10
% on risperidone after 1 
yr
60.7% 60.7% 59.3% 57.9% 56.5% 55.1%
Total QALYs (disc) 3.622 3.622 3.618 3.615 3.611 3.607
Costs 
(discounted by 
component)
Home (pp) €0 €0 €0 €0 €0 €0
Home (ia) €254 €254 €255 €256 €257 €258
Sheltered Living €7,120 €7,124 €7,136 €7,145 €7,159 €7,182
Day Care €35,188 €35,229 €35,329 €35,479 €35,654 €35,758
Hospital €37,124 €37,088 €37,440 €37,700 €37,971 €38,267
Long-term care institution €958 €953 €966 €965 €972 €973
Psych Visits €952 €952 €954 €955 €957 €959
Drug Costs €8,012 €6,778 €6,772 €6,765 €6,760 €6,755
Total Discounted Costs €89,607 €88,378 €88,850 €89,265 €89,730 €90,152
E 0 0.004 0.007 0.011 0.015
C €1,230 €757 €343 -€123 -€544
ICUR - €196,243 €46,032 dominant dominant
PANSS = positive and negative syndrome scale, QALYs = quality adjusted life years, ΔE = incremental effects of branded risperidone vs. generic 
risperidone, ΔC = incremental costs of branded risperidone vs. generic risperidone, ICUR = incremental cost utility ratio of branded risperidone vs. 
generic risperidone.BMC Health Services Research 2009, 9:32 http://www.biomedcentral.com/1472-6963/9/32
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difference in medication costs must be bridged by larger
treatment setting cost-savings (and larger health-benefits)
which can only be achieved by larger compliance differ-
ences.
The results of the EISI analysis are presented in Figure 3
which shows that the larger the size of the trial and the
larger the incremental probability that switching to
generic risperidone results in non-compliance, the higher
the probability that branded risperidone will be cost-
effective at a WTP of  40,000 per QALY gained. For exam-
ple Figure 3 shows that for a trial including 200 patients
that finds a 7% probability of becoming non-compliant
after generic substitution, the expected probability of
branded risperidone being cost-effective is 85% at a WTP
of  40,000 per QALY gained. Also, it should be noted that
there is a declining marginal benefit of adding one more
patient. In other words, adding one patient to a group of
200 does not increase certainty as much as adding one
patient to a group of 10 people for instance.
Discussion
The pharmaco-economic DES model predicts that generic
substitution of risperidone in patients suffering from
schizophrenia in Germany may not be cost-effective/cost-
saving if it involves a loss in compliance. Patients who
become non-compliant after generic substitution have
less symptom control which increases the probability of
being treated in a more intensive and thus costly facility
(e.g. hospital). The costs incurred in such treatment set-
tings (partially) counteract the drug cost savings resulting
from generic substitution. Also, less symptom control in
patients suffering from schizophrenia negatively affects
the quality of life. The balance between drug-cost savings
on one hand and additional treatment setting costs and
worse quality of life on the other hand depends on the
degree of the compliance loss and the difference between
the branded and the generic price. The smaller the price
difference, the smaller the compliances loss needs to be to
offset the drug cost-savings.
Kluznik et al. also acknowledge that generic substitution
in schizophrenia may not be cost-saving due to decreased
symptom control.[30] However in their study they con-
sidered clozapine. In this study, lower symptom control
after generic substitution was caused by a clinical differ-
ence between both compounds instead of less compliance
with generic clozapine. In fact, both tablets looked identi-
Incremental effects and costs for various compliance differences (including linear lines) Figure 1
Incremental effects and costs for various compliance differences (including linear lines).
-0.0060
-0.0040
-0.0020
0.0000
0.0020
0.0040
0.0060
0.0080
0.0100
0.0120
0.0140
0.0160
0.0% 2.5% 5.0% 7.5% 10.0%
Probability of becoming non-compliant after generic substitution
I
n
c
r
e
m
e
n
t
a
l
 
E
f
f
e
c
t
s
 
(
Q
A
L
Y
s
)
-€600
-€400
-€200
€0
€200
€400
€600
€800
€1,000
€1,200
€1,400
€1,600
I
n
c
r
e
m
e
n
t
a
l
 
C
o
s
t
s
Incremental effects of branded risperidone
Incremental costs of branded risperidone
Linear fit of incremental costs
Linear fit of incremental effectsBMC Health Services Research 2009, 9:32 http://www.biomedcentral.com/1472-6963/9/32
Page 6 of 9
(page number not for citation purposes)
cal to avoid patients finding out they were switched to a
generic alternative.
To the best of the authors' knowledge, no study has yet
been conducted that quantifies the incremental probabil-
ity to become non-compliant after generic substitution in
patients suffering from schizophrenia. If such a trial
would be conducted, the validity of the present compli-
ance loss assumptions can be tested according to the trial
results. Also, an EISI analysis was conducted, providing a
tool to relate the findings of this trial (and corresponding
uncertainty) to the probability that staying on branded
risperidone would be cost-effective compared to generic
substitution.
For a psychiatrist it is difficult to accurately estimate the
additional risk of non-compliance after generic substitu-
tion for a particular patient. As reported by Fleischhacker
Estimated Incremental Cost Utility Ratio at various compliance losses after generic substitution Figure 2
Estimated Incremental Cost Utility Ratio at various compliance losses after generic substitution. *At a willing-
ness to pay of €40,000 per QALY gained.
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Table 2: Compliance loss thresholds for various price levels of generic risperidone at which staying on branded risperidone is cost-
effective and dominant
Price reduction for generic risperidone 
(compared to branded price)
Min. compl. loss† for cost-effectiveness* Min. compl. loss† for dominance
20% 2.8% 3.7%
30% 4.1% 5.5%
40% 5.2% 6.9%
50% 6.7% 8.8%
60% 7.9% 10.5%
† Only applied to the three least intensive treatment settings
*At a willingness to pay of €40,000 per QALY gainedBMC Health Services Research 2009, 9:32 http://www.biomedcentral.com/1472-6963/9/32
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et al., there are several factors influencing compliance,
therefore also affecting the additional risk of non-compli-
ance after generic substitution.[8] Careful consideration
of these factors may help a psychiatrist in assessing the
likelihood that a particular patient may end up being non-
compliant after generic substitution. If a patient showed
more symptoms or ended up in a relapse after a previous
substitution, it is probably not cost-effective, nor in the
interest of the patient to substitute his medication with a
generic alternative. Also, if a patient has a negative attitude
towards changes in general or suffers from paranoia or
delusions, generic substitution is more likely to result in
non-compliance. On the other hand it is not unlikely that
paranoid or delusional patients will already be non-com-
pliant on the current treatment. Patients having a support-
ive environment are more likely to be compliant than
patients living alone.[31] Similarly, one may expect that
generic substitution is less likely to result in non-compli-
ance for patients living in a supportive environment. On
the other hand it is essential that a patient's environment
has a positive attitude towards treatment changes and is
able to understand and explain the rationale. This may
prove to be difficult in cases for which a patient is stable
on a current regimen. A cornerstone of treatment compli-
ance is the therapeutic relationship between the clinician
and the patient.[32] A structured nature of the therapy is
a signal to the patient that his therapy is of importance.[8]
A stable therapy structure may be impaired by changing a
patient's medication.
The current DES model is an adaptation of previous mod-
els[14,15,18] and distinguishes itself from the other mod-
els in that it specifically addresses the issue of compliance
loss with generic substitution of risperidone in Germany.
DES is a suitable and flexible technique for modelling het-
erogeneous and complex diseases with numerous interde-
pendencies such as schizophrenia. Model inputs and
design were based on data from the literature whenever
possible. Nevertheless, due to the lack of long-term data,
it was unavoidable to make a few assumptions which have
been substantiated by previously consulted experts. To
validate the model, outputs were compared with pub-
lished sources. Schulenburg et al. reported direct schizo-
phrenia cost of  14,204 per patient in Germany in
1996.[33] If we adjust this figure to 2007 costs using the
German price consumer index[34], this would give an
estimated figure of approximately  16,800. The annual
costs in the DES model ( 18,000) are very close to this fig-
Probability that staying on branded risperidone will be cost-effective (at a WTP of €40,000 per QALY gained) compared to  generic substitution (at various levels of probability of becoming non-compliant after generic substitution and with various  number of patients included) Figure 3
Probability that staying on branded risperidone will be cost-effective (at a WTP of €40,000 per QALY gained) 
compared to generic substitution (at various levels of probability of becoming non-compliant after generic 
substitution and with various number of patients included).
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ure. The model estimates that patients spend 2.1 out of 5
years in relapse, which is very close to the estimate of 40%
reported by Mason et al.[35] Hence, the model results
seem to be in line with published estimates.
Conclusion
It is estimated that at a WTP threshold of  40,000 per
QALY gained, it is cost-effective to keep a patient with
schizophrenia in Germany on branded risperidone
instead of switching him/her to generic risperidone
(assuming a 40% reduction in medication costs), if the
incremental probability that he/she will become non-
compliant after generic substitution is more than 5.2%.
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